Pangaea Data, AstraZeneca Leverage AI To Detect Rare Diseases

Pangaea Data, a company specializing in identifying patients with hard-to-diagnose conditions, has entered a multi-year collaboration with AstraZeneca to scale the use of multimodal, clinical-grade AI that helps detect disease earlier and connect patients to appropriate treatments and clinical trials. Supported by Microsoft and NVIDIA, the partnership will integrate Pangaea’s AI capabilities directly into clinical workflows, enabling real-time, guideline-informed insights using imaging, clinical, pathology, genomic, and real-world data.

The collaboration builds on Pangaea’s earlier work with Alexion, AstraZeneca’s rare-disease division, to validate an AI tool for detecting hypophosphatasia in adults. Pangaea’s platform, Pallux, already uses AI and clinical guidelines to find undertreated or undiagnosed patients with conditions such as hypertrophic cardiomyopathy, Cushing’s syndrome, COPD, chronic kidney disease, lupus, and others. CEO Vibhor Gupta said the goal is to close care gaps by identifying patients sooner and routing them to therapies and trials more effectively.

Under the agreement, AstraZeneca will support the development, validation, and deployment of Pangaea’s enterprise platform, which leverages Microsoft’s generative and predictive AI and NVIDIA’s accelerated compute. The platform will be integrated with tools such as Microsoft Dragon Copilot, enabling real-time conversational analysis and clinical recommendations. The collaboration will use Microsoft Azure AI, Microsoft Fabric, and confidential computing to train multimodal models securely and share data across global partners.

Together, Pangaea and AstraZeneca will work to identify untreated, undertreated, or misdiagnosed patients within EHR systems, create cohorts for clinical management, and support clinical trial recruitment. Gupta said the partnership reflects a shared commitment to responsible, secure, and impactful AI in healthcare, and marks a major step toward more precise and equitable patient care worldwide.